Can cabozantinib be used to treat lung adenocarcinoma? Indications and Medication Guide

Cabozantinib is a multi-target tyrosine kinase inhibitor that mainly acts on MET and VEGFR, AXL, RET and other pathways have been approved in the treatment of multiple solid tumors, including advanced renal cell carcinoma, hepatocellular carcinoma and medullary thyroid cancer. In the field of lung cancer, especially non-small cell lung cancer (NSCLC), cabozantinib has also shown certain therapeutic potential, especially in patients with lung adenocarcinoma with MET gene alterations.

Research has found that some patients with lung adenocarcinoma have MET amplification or MET exon 14 skipping mutation (METex14 skipping mutation). Such mutations can cause cancer cells to become resistant to traditional treatments. Cabozantinib is expected to improve the prognosis of these patients by inhibiting the MET signaling pathway. In some early clinical studies, cabozantinib has shown good disease control rates in patients with MET mutation-positive non-small cell lung cancer, especially in patients who are resistant to EGFR or ALK targeted therapy and may become a later-line treatment option.

At present, cabozantinib has not been officially included in the first-line treatment standard for lung adenocarcinoma worldwide, but its application in MET abnormal lung cancer is gradually being supported by clinical trials. A number of international studies are evaluating its efficacy as a single agent or in combination with immunotherapy and chemotherapy, and some guidelines have begun to mention it as a treatment alternative for MET-positive lung cancer. For a specific patient, whether to use cabozantinib depends on a comprehensive evaluation of genetic testing results and previous medication history.

Overall, cabozantinib has potential value in lung adenocarcinoma, especially in METnon-small cell lung cancer. Although it has not yet been widely approved as a standard treatment for lung cancer, for patients with previous treatment failure and specific molecular changes, using cabozantinib under the guidance of a doctor or participating in relevant clinical studies may provide new treatment directions for disease control. During the medication process, it is still necessary to pay close attention to possible adverse reactions, such as hypertension, hand-foot syndrome, abnormal liver function, etc., to ensure the safety and effectiveness of the treatment.

Reference materials:https://en.wikipedia.org/wiki/Cabozantinib